<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36471413</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1745-6215</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>05</Day></PubDate></JournalIssue><Title>Trials</Title><ISOAbbreviation>Trials</ISOAbbreviation></Journal><ArticleTitle>Lithium carbonate in amyotrophic lateral sclerosis patients homozygous for the C-allele at SNP rs12608932 in UNC13A: protocol for a confirmatory, randomized, group-sequential, event-driven, double-blind, placebo-controlled trial.</ArticleTitle><Pagination><StartPage>978</StartPage><MedlinePgn>978</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">978</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13063-022-06906-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Given the large genetic heterogeneity in amyotrophic lateral sclerosis (ALS), it seems likely that genetic subgroups may benefit differently from treatment. An exploratory meta-analysis identified that patients homozygous for the C-allele at SNP rs12608932, a single nucleotide polymorphism in the gene UNC13A, had a statistically significant survival benefit when treated with lithium carbonate. We aim to confirm the efficacy of lithium carbonate on the time to death or respiratory insufficiency in patients with ALS homozygous for the C-allele at SNP rs12608932 in UNC13A.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A randomized, group-sequential, event-driven, double-blind, placebo-controlled trial will be conducted in 15 sites across Europe and Australia. Patients will be genotyped for UNC13A; those homozygous for the C-allele at SNP rs12608932 will be eligible. Patients must have a diagnosis of ALS according to the revised El Escorial criteria, and a TRICALS risk-profile score between -6.0 and -2.0. An expected number of 1200 patients will be screened in order to enroll a target sample size of 171 patients. Patients will be randomly allocated in a 2:1 ratio to lithium carbonate or matching placebo, and treated for a maximum duration of 24 months. The primary endpoint is the time to death or respiratory insufficiency, whichever occurs first. Key secondary endpoints include functional decline, respiratory function, quality of life, tolerability, and safety. An interim analysis for futility and efficacy will be conducted after the occurrence of 41 events.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Lithium carbonate has been proven to be safe and well-tolerated in patients with ALS. Given the favorable safety profile, the potential benefits are considered to outweigh the burden and risks associated with study participation. This study may provide conclusive evidence about the life-prolonging potential of lithium carbonate in a genetic ALS subgroup.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">EudraCT number 2020-000579-19 . Registered on 29 March 2021.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Willemse</LastName><ForeName>Sean W</ForeName><Initials>SW</Initials><Identifier Source="ORCID">0000-0002-0198-5740</Identifier><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roes</LastName><ForeName>Kit C B</ForeName><Initials>KCB</Initials><AffiliationInfo><Affiliation>Department of Health Evidence, Radboud UMC, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Damme</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardiman</LastName><ForeName>Orla</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Neurology, National Neuroscience Centre, Beaumont Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>FutureNeuro SFI Research Centre, Royal College of Surgeons in Ireland, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ingre</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Povedano</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Functional Unit of Amyotrophic Lateral Sclerosis (UFELA), Service of Neurology, Bellvitge University Hospital, Hospitalet de Llobregat, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wray</LastName><ForeName>Naomi R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gijzen</LastName><ForeName>Marleen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Genetics, UMC Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Pagter</LastName><ForeName>Mirjam S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Department of Genetics, UMC Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demaegd</LastName><ForeName>Koen C</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Janse</LastName><ForeName>Annemarie F C</ForeName><Initials>AFC</Initials><AffiliationInfo><Affiliation>TRICALS, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vink</LastName><ForeName>Roel G</ForeName><Initials>RG</Initials><AffiliationInfo><Affiliation>TRICALS, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sleutjes</LastName><ForeName>Boudewijn T H M</ForeName><Initials>BTHM</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chi&#xf2;</LastName><ForeName>Adriano</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology, AOU Citt&#xe0; della Salute e della Scienza Hospital of Turin, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corcia</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centre Constitutif SLA, CHRU de Tours - F&#xe9;d&#xe9;ration des centres SLA Tours-Limoges, LitORALS, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reviers</LastName><ForeName>Evy</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>European Organization for Professionals and Patients with ALS (EUpALS) &amp; ALS Liga Belgium, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Chalabi</LastName><ForeName>Ammar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, King's College London, Maurice Wohl Clinical Neuroscience Institute, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, King's College Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiernan</LastName><ForeName>Matthew C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brain and Mind Centre, University of Sydney, Sydney, New South Wales, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Berg</LastName><ForeName>Leonard H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Es</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Eijk</LastName><ForeName>Ruben P A</ForeName><Initials>RPA</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht, Utrecht, The Netherlands. R.P.A.vanEijk-2@umcutrecht.nl.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biostatistics and Research Support, Julius Centre for Health Sciences and Primary Care, Utrecht University, Utrecht, Netherlands. R.P.A.vanEijk-2@umcutrecht.nl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ALCHALABI-DOBSON/APR14/829-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/R024804/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>T003519N</GrantID><Agency>Fonds Wetenschappelijk Onderzoek</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trials</MedlineTA><NlmUniqueID>101263253</NlmUniqueID><ISSNLinking>1745-6215</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012131" MajorTopicYN="Y">Respiratory Insufficiency</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015201" MajorTopicYN="N">Meta-Analysis as Topic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Lithium carbonate</Keyword><Keyword MajorTopicYN="N">Randomized controlled trial</Keyword><Keyword MajorTopicYN="N">SNP rs12608932</Keyword><Keyword MajorTopicYN="N">UNC13A</Keyword></KeywordList><CoiStatement>SWW, KCBR, OH, CI, MP, NRW, MG, MdP, KCD, AFCJ, RGV, BTHMS, PC, ER, AAC, and RPAvE declare no competing interests. PVD has served in advisory boards for Biogen, CSL Behring, Alexion Pharmaceuticals, Ferrer, QurAlis, Cytokinetics, Argenx, UCB, Muna Therapeutics, Alector, Augustine Therapeutics, and VectorY (paid to institution). AC serves on scientific advisory boards for Mitsubishi Tanabe, Biogen, Roche, Denali Pharma, Cytokinetics, Lilly, and Amylyx Pharmaceuticals and has received a research grant from Biogen. MCK is funded by the National Health and Medical Research Council of Australia Program Grant (#1132524), Partnership Project (#1153439) and Practitioner Fellowship (1156093).LHvdB declares fees to his institution from Biogen, Wave, Amylyx, Ferrer, and Cytokinetics for being on a scientific advisory board; fees to his institution from Amylyx for a lecture; an unrestricted educational grant from Takeda; and is the Chair of ENCALS and TRICALS. MAvE has consulted for Biogen, and has received travel grants from Shire (formerly Baxalta) and serves as medical monitor for Ferrer in the ADORE trial (NCT05178810), other funding sources include the Netherlands Organization for Health Research and Development (Vidi scheme), The Thierry Latran Foundation, Motor Neurone Disease Association, FIGHT-MND and the ALS Foundation Netherlands. Several authors of this publication are member of the European Reference Network for Rare Neuromuscular Diseases (ERN-NMD).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>5</Day><Hour>23</Hour><Minute>59</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36471413</ArticleId><ArticleId IdType="pmc">PMC9721045</ArticleId><ArticleId IdType="doi">10.1186/s13063-022-06906-5</ArticleId><ArticleId IdType="pii">10.1186/s13063-022-06906-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, et al. Amyotrophic lateral sclerosis. Lancet. 2017;390(10107):2084&#x2013;2098. doi: 10.1016/S0140-6736(17)31287-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic Lateral Sclerosis. N Engl J Med. 2017;377(2):162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Eijk RPA, Westeneng HJ, Nikolakopoulos S, Verhagen IE, Van Es MA, Eijkemans MJC, et al. Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials. Neurology. 2019;92(5):E451&#x2013;E460. doi: 10.1212/WNL.0000000000006855.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006855</ArticleId><ArticleId IdType="pmc">PMC6369899</ArticleId><ArticleId IdType="pubmed">30626653</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston CA, Stanton BR, Turner MR, Gray R, Blunt AHM, Butt D, et al. Amyotrophic lateral sclerosis in an urban setting: A population based study of inner city London. J Neurol. 2006;253(12):1642&#x2013;1643. doi: 10.1007/s00415-006-0195-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-006-0195-y</ArticleId><ArticleId IdType="pubmed">17219036</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet. 1996;347(9013):1425&#x2013;1431. doi: 10.1016/S0140-6736(96)91680-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(96)91680-3</ArticleId><ArticleId IdType="pubmed">8676624</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Vucic S, Talbot K, McDermott CJ, Hardiman O, Shefner JM, et al. Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nat Rev Neurol. 2021;17(2):104&#x2013;118. doi: 10.1038/s41582-020-00434-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-00434-z</ArticleId><ArticleId IdType="pmc">PMC7747476</ArticleId><ArticleId IdType="pubmed">33340024</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, Kliest T, McDermott CJ, Roes KCB, Van Damme P, Chio A, et al. TRICALS: creating a highway toward a cure. Amyotroph Lateral Scler Front Degener. 2020;21(7&#x2013;8):496&#x2013;501. doi: 10.1080/21678421.2020.1788092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1788092</ArticleId><ArticleId IdType="pubmed">32643415</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Eijk RPA, Jones AR, Sproviero W, Shatunov A, Shaw PJ, Leigh PN, et al. Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology. 2017;89(18):1915&#x2013;1922. doi: 10.1212/WNL.0000000000004606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004606</ArticleId><ArticleId IdType="pmc">PMC5664299</ArticleId><ArticleId IdType="pubmed">28978660</ArticleId></ArticleIdList></Reference><Reference><Citation>Cade JFJ. Lithium salts in the treatment of psychotic excitement. Med J Aust. 1949;2(10):349&#x2013;352. doi: 10.5694/j.1326-5377.1949.tb36912.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.5694/j.1326-5377.1949.tb36912.x</ArticleId><ArticleId IdType="pubmed">18142718</ArticleId></ArticleIdList></Reference><Reference><Citation>Schou M, Juel-Nielsen N, Stromgren E, Voldby H. The treatment of manic psychoses by the administration of lithium salts. J Neurol Neurosurg Psychiatry. 1954;17(4):250&#x2013;260. doi: 10.1136/jnnp.17.4.250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.17.4.250</ArticleId><ArticleId IdType="pmc">PMC503195</ArticleId><ArticleId IdType="pubmed">13212414</ArticleId></ArticleIdList></Reference><Reference><Citation>Lees AJ. Lithium: A slow burner. J Neurol Neurosurg Psychiatry. 2020;91(4):335&#x2013;337. doi: 10.1136/jnnp-2019-322382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-322382</ArticleId><ArticleId IdType="pubmed">32179728</ArticleId></ArticleIdList></Reference><Reference><Citation>Forlenza OV, De-Paula VJR, Diniz BSO. Neuroprotective effects of lithium: Implications for the treatment of Alzheimer&#x2019;s disease and related neurodegenerative disorders. ACS Chem Neurosci. 2014;5(6):443&#x2013;450. doi: 10.1021/cn5000309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/cn5000309</ArticleId><ArticleId IdType="pmc">PMC4063497</ArticleId><ArticleId IdType="pubmed">24766396</ArticleId></ArticleIdList></Reference><Reference><Citation>Broeke JHP, Roelandse M, Luteijn MJ, Boiko T, Matus A, Toonen RF, et al. Munc18 and Munc13 regulate early neurite outgrowth. Biol Cell. 2010;102(8):479&#x2013;488. doi: 10.1042/BC20100036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BC20100036</ArticleId><ArticleId IdType="pmc">PMC2895782</ArticleId><ArticleId IdType="pubmed">20497124</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Allen C, Counsell C, Farrin A, Dickie B, Kelly J, et al. Lithium in patients with amyotrophic lateral sclerosis (LiCALS): A phase 3 multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2013;12(4):339&#x2013;345. doi: 10.1016/S1474-4422(13)70037-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70037-1</ArticleId><ArticleId IdType="pmc">PMC3610091</ArticleId><ArticleId IdType="pubmed">23453347</ArticleId></ArticleIdList></Reference><Reference><Citation>Verstraete E, Veldink JH, Huisman MHB, Draak T, Uijtendaal EV, Van Der Kooi AJ, et al. Lithium lacks effect on survival in amyotrophic lateral sclerosis: A phase IIb randomised sequential trial. J Neurol Neurosurg Psychiatry. 2012;83(5):557&#x2013;564. doi: 10.1136/jnnp-2011-302021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2011-302021</ArticleId><ArticleId IdType="pubmed">22378918</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>TRICALS. Risk Profile Calculator. https://tricals.shinyapps.io/risk-profile/. Accessed 21 Sep 2022.</Citation></Reference><Reference><Citation>van Eijk RPA, Nikolakopoulos S, Roes KCB, Kendall L, Han SS, Lavrov A, et al. Innovating Clinical Trials for Amyotrophic Lateral Sclerosis: Challenging the Established Order. Neurology. 2021;97(11):528&#x2013;536. doi: 10.1212/WNL.0000000000012545.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000012545</ArticleId><ArticleId IdType="pmc">PMC8456357</ArticleId><ArticleId IdType="pubmed">34315786</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng HJ, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17(5):423&#x2013;433. doi: 10.1016/S1474-4422(18)30089-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30089-9</ArticleId><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Borghero G, Calvo A, Capasso M, Caponnetto C, Corbo M, et al. Lithium carbonate in amyotrophic lateral sclerosis: Lack of efficacy in a dose-finding trial. Neurology. 2010;75(7):619&#x2013;625. doi: 10.1212/WNL.0b013e3181ed9e7c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181ed9e7c</ArticleId><ArticleId IdType="pubmed">20702794</ArticleId></ArticleIdList></Reference><Reference><Citation>Haddad P, Wieck A, Yarrow M, Denham P. The Lithium Side Effects Rating Scale (LISERS); development of a self-rating instrument. Eur Neuropsychopharmacol. 1999;9:231&#x2013;232.</Citation></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci. 1999;169(1&#x2013;2):13&#x2013;21. doi: 10.1016/S0022-510X(99)00210-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann P, Levy G, Thompson JLP, DelBene ML, Battista V, Gordon PH, et al. The ALSFRSr predicts survival time in an ALS clinic population. Neurology. 2005;64(1):38&#x2013;43. doi: 10.1212/01.WNL.0000148648.38313.64.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000148648.38313.64</ArticleId><ArticleId IdType="pubmed">15642901</ArticleId></ArticleIdList></Reference><Reference><Citation>Czaplinski A, Yen AA, Appel SH. Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry. 2006;77(3):390&#x2013;392. doi: 10.1136/jnnp.2005.072660.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2005.072660</ArticleId><ArticleId IdType="pmc">PMC2077717</ArticleId><ArticleId IdType="pubmed">16484652</ArticleId></ArticleIdList></Reference><Reference><Citation>Quanjer PH, Stanojevic S. Do the global lung function initiative 2012 equations fit my population? Eur Respir J. 2016;48(6):1782&#x2013;1785. doi: 10.1183/13993003.01757-2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01757-2016</ArticleId><ArticleId IdType="pubmed">27811067</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Eijk RPA, Eijkemans MJC, Ferguson TA, Nikolakopoulos S, Veldink JH, Van Den Berg LH. Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials. J Neurol Neurosurg Psychiatry. 2018;89(2):156&#x2013;161. doi: 10.1136/jnnp-2017-317077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-317077</ArticleId><ArticleId IdType="pmc">PMC5800333</ArticleId><ArticleId IdType="pubmed">29084868</ArticleId></ArticleIdList></Reference><Reference><Citation>Tetsuka S, Morita M, Ikeguchi K, Nakano I. Utility of cystatin C for renal function in amyotrophic lateral sclerosis. Acta Neurol Scand. 2013;128(6):386&#x2013;390. doi: 10.1111/ane.12134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ane.12134</ArticleId><ArticleId IdType="pubmed">23802939</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Hammond ER, Mora G, Bonito V, Filippini G. Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2015;86(1):38&#x2013;44. doi: 10.1136/jnnp-2013-306589.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2013-306589</ArticleId><ArticleId IdType="pubmed">24336810</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R, Jones A, Jivraj N, Steen IN, Young CA, Shaw PJ, et al. Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials. J Neurol Neurosurg Psychiatry. 2015;86(1):45&#x2013;49. doi: 10.1136/jnnp-2013-306865.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2013-306865</ArticleId><ArticleId IdType="pubmed">24463480</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Wei QQ, Chen Y, Cao B, Ou RW, Hou Y, et al. Clinical staging of amyotrophic lateral sclerosis in Chinese patients. Front Neurol. 2018;9:1&#x2013;9. doi: 10.3389/fneur.2018.00442.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.00442</ArticleId><ArticleId IdType="pmc">PMC6018204</ArticleId><ArticleId IdType="pubmed">29971035</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepheard SR, Wuu J, Cardoso M, Wiklendt L, Dinning PG, Chataway T, et al. Urinary p75ECD: A prognostic, disease progression, and pharmacodynamic biomarker in ALS. Neurology. 2017;88(12):1137&#x2013;1143. doi: 10.1212/WNL.0000000000003741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003741</ArticleId><ArticleId IdType="pmc">PMC5373786</ArticleId><ArticleId IdType="pubmed">28228570</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH, Macdonald-Wallis C, Gray E, Pearce N, Petzold A, Norgren N, et al. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015;84(22):2247&#x2013;2257. doi: 10.1212/WNL.0000000000001642.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001642</ArticleId><ArticleId IdType="pmc">PMC4456658</ArticleId><ArticleId IdType="pubmed">25934855</ArticleId></ArticleIdList></Reference><Reference><Citation>Crockford C, Newton J, Lonergan K, Chiwera T, Booth T, Chandran S, et al. ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS. Neurology. 2018;91(15):E1370&#x2013;E1380. doi: 10.1212/WNL.0000000000006317.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006317</ArticleId><ArticleId IdType="pmc">PMC6177274</ArticleId><ArticleId IdType="pubmed">30209236</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahams S, Newton J, Niven E, Foley J, Bak TH. Screening for cognition and behaviour changes in ALS. Amyotroph Lateral Scler Front Degener. 2014;15(1&#x2013;2):9&#x2013;14. doi: 10.3109/21678421.2013.805784.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.805784</ArticleId><ArticleId IdType="pubmed">23781974</ArticleId></ArticleIdList></Reference><Reference><Citation>Raaphorst J, Beeldman E, Schmand B, Berkhout J, Linssen WHJP, Van Den Berg LH, et al. The ALS-FTD-Q: A new screening tool for behavioral disturbances in ALS. Neurology. 2012;79(13):1377&#x2013;1383. doi: 10.1212/WNL.0b013e31826c1aa1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31826c1aa1</ArticleId><ArticleId IdType="pubmed">22972650</ArticleId></ArticleIdList></Reference><Reference><Citation>De Boer AGEM, Van Lanschot JJB, Stalmeier PFM, Van Sandick JW, Hulscher JBF, De Haes JCJM, et al. Is a single-item visual analogue scale as valid, reliable and responsive as multi-item scales in measuring quality of life? Qual Life Res. 2004;13(2):311&#x2013;320. doi: 10.1023/B:QURE.0000018499.64574.1f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/B:QURE.0000018499.64574.1f</ArticleId><ArticleId IdType="pubmed">15085903</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones AR, Jivraj N, Balendra R, Murphy C, Kelly J, Thornhill M, et al. Health utility decreases with increasing clinical stage in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Front Degener. 2014;15(3&#x2013;4):285&#x2013;291. doi: 10.3109/21678421.2013.872149.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.872149</ArticleId><ArticleId IdType="pubmed">24641613</ArticleId></ArticleIdList></Reference><Reference><Citation>Maathuis EM, Drenthen J, Van Doorn PA, Visser GH, Blok JH. The CMAP scan as a tool to monitor disease progression in ALS and PMA. Amyotroph Lateral Scler Front Degener. 2013;14(3):217&#x2013;223. doi: 10.3109/21678421.2012.732079.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2012.732079</ArticleId><ArticleId IdType="pubmed">23134509</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson RD, Ridall GR, Pettitt AN, McCombe PA, Daube JR. The stimulus-response curve and motor unit variability in normal subjects and subjects with amyotrophic lateral sclerosis. Muscle Nerve. 2006;34(1):34&#x2013;43. doi: 10.1002/mus.20561.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.20561</ArticleId><ArticleId IdType="pubmed">16634059</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson RD, Ridall PG, Hutchinson NM, Pettitt AN, McCombe PA. Bayesian statistical mune method. Muscle Nerve. 2007;36(2):206&#x2013;213. doi: 10.1002/mus.20805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.20805</ArticleId><ArticleId IdType="pubmed">17487869</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleutjes BTHM, Montfoort I, Maathuis EM, Drenthen J, van Doorn PA, Visser GH, et al. CMAP scan discontinuities: Automated detection and relation to motor unit loss. Clin Neurophysiol. 2014;125(2):388&#x2013;395. doi: 10.1016/j.clinph.2013.07.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2013.07.016</ArticleId><ArticleId IdType="pubmed">23993681</ArticleId></ArticleIdList></Reference><Reference><Citation>Drenthen J, Maathuis EM, Visser GH, van Doorn PA, Blok JH, Jacobs BC. Limb motor nerve dysfunction in Miller Fisher syndrome. J Peripher Nerv Syst. 2013;18(1):25&#x2013;29. doi: 10.1111/jns5.12003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jns5.12003</ArticleId><ArticleId IdType="pubmed">23521640</ArticleId></ArticleIdList></Reference><Reference><Citation>Maathuis EM, Henderson RD, Drenthen J, Hutchinson NM, Daube JR, Blok JH, et al. Optimal stimulation settings for CMAP scan registrations. J Brachial Plexus Peripheral Nerve Inj. 2012;7:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3377546</ArticleId><ArticleId IdType="pubmed">22546084</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobsen AB, Bostock H, Tankisi H. Following disease progression in motor neuron disorders with 3 motor unit number estimation methods. Muscle Nerve. 2019;59(1):82&#x2013;87. doi: 10.1002/mus.26304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26304</ArticleId><ArticleId IdType="pubmed">30025164</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumann F, Henderson RD, Ridall PG, Pettitt AN, McCombe PA. Use of Bayesian MUNE to show differing rate of loss of motor units in subgroups of ALS. Clin Neurophysiol. 2012;123(12):2446&#x2013;2453. doi: 10.1016/j.clinph.2012.04.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2012.04.022</ArticleId><ArticleId IdType="pubmed">22608482</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleutjes BTHM, Bystrup Jacobsen A, Tankisi H, Gorkem Sirin N, Emre Oge A, Henderson RD, et al. Advancing disease monitoring of amyotrophic lateral sclerosis with the compound muscle action potential scan. Clin Neurophysiol. 2021;132(12):3152&#x2013;3159. doi: 10.1016/j.clinph.2021.09.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2021.09.014</ArticleId><ArticleId IdType="pubmed">34749234</ArticleId></ArticleIdList></Reference><Reference><Citation>TRICALS. Register as a patient in the TRICALS registry. https://www.tricals.org/register-castor/. Accessed 29 Sep 2022.</Citation></Reference><Reference><Citation>Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: The global lung function 2012 equations. Eur Respir J. 2012;40(6):1324&#x2013;1343. doi: 10.1183/09031936.00080312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.00080312</ArticleId><ArticleId IdType="pmc">PMC3786581</ArticleId><ArticleId IdType="pubmed">22743675</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura F, Fujimura C, Ishida S, Nakajima H, Furutama D, Uehara H, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66(2):265&#x2013;267. doi: 10.1212/01.wnl.0000194316.91908.8a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000194316.91908.8a</ArticleId><ArticleId IdType="pubmed">16434671</ArticleId></ArticleIdList></Reference><Reference><Citation>Center for Drug Evaluation and Research . Amyotrophic Lateral Sclerosis: Developing Drugs for Treatment Guidance for Industry. 2019.</Citation></Reference><Reference><Citation>European Medicines Agency - Committee for Medicinal Products for Human Use . Guideline on clinical investigation of medicinal products for the treatment of amyotrophic lateral sclerosis (ALS) 2015.</Citation></Reference><Reference><Citation>van Eijk RPA, Eijkemans MJC, Rizopoulos D, van den Berg LH, Nikolakopoulos S. Comparing methods to combine functional loss and mortality in clinical trials for amyotrophic lateral sclerosis. Clin Epidemiol. 2018;10:333&#x2013;341. doi: 10.2147/CLEP.S153196.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CLEP.S153196</ArticleId><ArticleId IdType="pmc">PMC5865572</ArticleId><ArticleId IdType="pubmed">29593436</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizopoulos D. Joint models for longitudinal and time-to-event data&#xa0;: with applications in R. Boca Raton: Chapman &amp; Hall/CRC; 2012.</Citation></Reference><Reference><Citation>Van Eijk RPA, Nikolakopoulos S, Roes KCB, Middelkoop BM, Ferguson TA, Shaw PJ, et al. Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials. J Neurol Neurosurg Psychiatry. 2019;90(12):1331&#x2013;1337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6902062</ArticleId><ArticleId IdType="pubmed">31292200</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Hendrix S, Dickson SP, Knowlton N, Macklin EA, Berry JD, et al. Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle Nerve. 2021;63(1):31&#x2013;39. doi: 10.1002/mus.27091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27091</ArticleId><ArticleId IdType="pmc">PMC7820979</ArticleId><ArticleId IdType="pubmed">33063909</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller TM, Cudkowicz ME, Genge A, Shaw PJ, Sobue G, Bucelli RC, et al. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2022;387(12):1099&#x2013;1110. doi: 10.1056/NEJMoa2204705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2204705</ArticleId><ArticleId IdType="pubmed">36129998</ArticleId></ArticleIdList></Reference><Reference><Citation>Salmon K, Kiernan MC, Kim SH, Andersen PM, Chio A, Van Den Berg LH, et al. The importance of offering early genetic testing in everyone with amyotrophic lateral sclerosis. Brain. 2022;145(4):1207&#x2013;1210. doi: 10.1093/brain/awab472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab472</ArticleId><ArticleId IdType="pmc">PMC9129091</ArticleId><ArticleId IdType="pubmed">35020823</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W, van der Spek RAA, Bakker MK, van Vugt JJFA, Hop PJ, Zwamborn RAJ, et al. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nat Genet. 2021;53(12):1636&#x2013;1648. doi: 10.1038/s41588-021-00973-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-021-00973-1</ArticleId><ArticleId IdType="pmc">PMC8648564</ArticleId><ArticleId IdType="pubmed">34873335</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Es MA, Veldink JH, Saris CGJ, Blauw HM, Van Vught PWJ, Birve A, et al. Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet. 2009;41(10):1083&#x2013;1087. doi: 10.1038/ng.442.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.442</ArticleId><ArticleId IdType="pubmed">19734901</ArticleId></ArticleIdList></Reference><Reference><Citation>Diekstra FP, van Vught PWJ, van Rheenen W, Koppers M, Pasterkamp RJ, van Es MA, et al. UNC13A is a modifier of survival in amyotrophic lateral sclerosis. Neurobiol Aging. 2012;33(3):630.e3&#x2013;630.e8. doi: 10.1016/j.neurobiolaging.2011.10.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2011.10.029</ArticleId><ArticleId IdType="pubmed">22118904</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan HHG, Westeneng HJ, van der Burgh HK, van Es MA, Bakker LA, van Veenhuijzen K, et al. The Distinct Traits of the UNC13A Polymorphism in Amyotrophic Lateral Sclerosis. Ann Neurol. 2020;88(4):796&#x2013;806. doi: 10.1002/ana.25841.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25841</ArticleId><ArticleId IdType="pmc">PMC7540607</ArticleId><ArticleId IdType="pubmed">32627229</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>